Bcl‐2‐negative IGH‐BCL2 translocation‐negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl‐2‐positive IGH‐BCL2 translocation‐positive follicular lymphoma
Authors:
- Yuichiro HamamotoYHYuichiro Hamamoto
- Yoji KukitaYKYoji Kukita
- Masanori KitamuraMKMasanori Kitamura
- Masako KurashigeMKMasako Kurashige
- Shigeo FujiSFShigeo Fuji
- Jun IshikawaJIJun Ishikawa
- Keiichiro HonmaKHKeiichiro Honma
- Tomoko WakasaTWTomoko Wakasa
- Mitsuyoshi HirokawaMHMitsuyoshi Hirokawa
- Ayana SuzukiASAyana Suzuki
- 7 April 2021
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 79 (4) , 521-532
Abstract
Aims: Follicular lymphoma (FL), comprising a minor subset of primary thyroid lymphomas, is divided into two groups based on Bcl‐2 expression and IGH‐BCL2 translocation. The clinicopathological features exhibited by Bcl‐2‐negative IGH‐BCL2 translocation‐negative FL of the thyroid (Bcl‐2–/IGH‐BCL2– tFL) are different from those of conventional FL; however, its lymphomagenesis remains unclear. Here, we collected samples from seven patients with Bcl‐2–/IGH‐BCL2– tFL to investigate their epigenetic and genetic aberrations.Methods and results: The immunohistochemical profiles of epigenetic modifiers and the methylation status of histones were examined, including EZH2, MLL2/KMT2D, CBP/CREBBP, EP300, H3K27me3 and H3K4me3, in Bcl‐2–/IGH‐BCL2– tFL and Bcl‐2‐positive IGH‐BCL2 translocation‐positive FL of the thyroid (Bcl‐2+/IGH‐BCL2+ tFL). Most Bcl‐2–/IGH‐BCL2– tFLs retained the positivity of epigenetic modifiers and lower expression of H3K27me3, although Bcl‐2+/IGH‐BCL2+ tFLs exhibited aberrant immunohistochemical patterns of EZH2 and CBP/CREBBP and overexpression of H3K27me3. Samples from seven cases were further analysed using targeted sequencing, focusing on the exons of 409 key tumour suppressor genes and oncogenes. Bcl‐2–/IGH‐BCL2– tFLs do not have pathogenic mutations of epigenetic modifiers, such as EZH2, MLL2/KMT2D, MLL3/KMT2C, EP300 and ARID1A, which have been reported in FLs in the literature, whereas Bcl‐2+/IGH‐BCL2+ tFLs are probably pathogenic/pathogenic missense mutations or frameshift mutations of these genes. Additionally, novel mutations in TET2 and EP400 were detected in Bcl‐2–/IGH‐BCL2– tFLs.Conclusions: Different genetic and epigenetic abnormalities might be involved in the oncogenesis of Bcl‐2–/IGH‐BCL2– tFLs from Bcl‐2+/IGH‐BCL2+ tFLs and other FLs.Keywords
This publication has 18 references indexed in Scilit:
- A global reference for human genetic variationNature, 2015
- The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseasesLeukemia, 2013
- GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2Angiogenesis, 2013
- Next‐generation‐sequencing‐based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemiaGenes, Chromosomes and Cancer, 2013
- EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferationsLeukemia, 2012
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- Follicular Lymphoma of the Thyroid GlandAmerican Journal of Surgical Pathology, 2009
- An RNAi Screen of Chromatin Proteins Identifies Tip60-p400 as a Regulator of Embryonic Stem Cell IdentityCell, 2008
- Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemiaProceedings of the National Academy of Sciences, 2008
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936Leukemia, 2003